Mersana Therapeutics’s stock craters after FDA halts trials of ovarian cancer treatment after patient deaths
June 15, 2023 at 14:07 PM EDT
Mersana's stock tumbles 58% to mark its biggest-ever one-day percentage decline since going public in 2018.
